<DOC>
	<DOCNO>NCT02381054</DOCNO>
	<brief_summary>The purpose study see Italian language version questionnaire symptom patient may cancer treatment understandable Italian speaking patient . The questionnaire call PRO-CTCAE , originally develop U.S. National Cancer Institute help get information patient ' symptom directly patient . The Italian version questionnaire use future study gain good understanding patient symptom .</brief_summary>
	<brief_title>Translation , Cross-cultural Adaptation Validation PRO-CTCAE Italian-speaking Cancer Patients</brief_title>
	<detailed_description>This study conduct two step . The first Italian translation cross cultural adaptation original US NCI 's version PRO-CTCAE questionnaire . The questionnaire translate administered sample 96 Italian patient . The second step validation Italian language version PRO-CTCAE questionnaire develop first step , phase 300 Italian patient enrol .</detailed_description>
	<criteria>Eligibility Criteria crosscultural adaption phase : Inclusion criterion : patient receive ( receive within 6 month ) chemotherapy radiotherapy curative palliative intent advance cancer one study sit ≥18 year age able speak understand Italian provide write informed consent Exclusion criterion : • Patients judge unable report symptom last seven day due cognitive impairment . Eligibility Criteria Validation phase : ≥18 year age . Patient able agrees return clinic follow day . Patient actively receive treatment cancer diagnosis Disease treatment match 1 6 follow cohort : Cohort Breast : Breast cancer patient still treatment already receive least one cycle adjuvant chemotherapy Cohort Lymphoma/Myeloma : Lymphoma/myeloma patient still treatment already receive least one cycle chemotherapy . Cohort Prostate/Bladder : Metastatic prostate bladder cancer patient still treatment already receive least one cycle chemotherapy . Cohort Lung : Metastatic lung cancer patient EITHER : still treatment already receive least one cycle chemotherapy biotherapy ( eg . EGFRTKI ) ; OR : receive daily radiation therapy last least 28 day ( concurrent chemotherapy allow radiation therapy end 4 week ) Cohort Colorectal : Metastatic colorectal cancer patient still treatment already receive least one cycle chemotherapy ( without associate biologic agent ) Cohort Head/Neck/Gastroesophageal : Head/neck/gastroesophageal cancer patient receive daily radiation therapy last least 28 day ( concurrent chemotherapy allow radiation therapy end 4 week ) Able complete questionnaire assistance . Providing informed write consent . Able speak understand Italian Clinically significant cognitive memory impairment opinion clinical research staff . Other important acute medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Patient report outcome</keyword>
</DOC>